



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: BCF-001 APPLICANT(S): Gaudreau APPLICATION NO.: 10/527,598 FILING DATE: November 3, 2005 GROUP NO.: 1654
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
/CB/	C1	Boulanger et al., "Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver," <u>Peptides</u> , 13:681-689 (1992).
/CB/	C2	Boulanger et al., "Proteolytic degradation of rat growth hormone-releasing factor(1-29) amide in rat pituitary and hypothalamus," <u>Brain Res.</u> , 616:39-47 (1993).
/CB/	C3	Boulanger et al., "Development of a site-directed polyclonal antibody against the pituitary growth hormone-releasing hormone receptor and its use to estimate GHRH receptor concentration in normal and hypothyroid rats," <u>Neuroendocrinology</u> , 70:117-127 (1999).
/CB/	C4	Cuttler et al., "Short stature and growth hormone therapy: A national study of physician recommended patterns," <u>JAMA</u> , 276(7):531-537 (1996).
/CB/	C5	Dubreuil et al., "Long-term growth hormone-releasing factor administration on growth hormone, insulin-like growth factor-I concentrations, and bone healing in the beagle," <u>Can. J. Vet. Res.</u> , 60:7-13 (1996).
/CB/	C6	Farmer et al., "Carcass composition and resistance to fasting in neonatal piglets born of sow immunized against somatostatin and/or receiving growth hormone-releasing factor injections during gestation," <u>Biol. Neonate</u> , 61:110-117 (1992).
/CB/	C7	Finklestein et al., "Insurance coverage, physician recommendations, and access to emerging treatments," <u>JAMA</u> , 279(9):663-668 (1998).
/CB/	C8	Gaudreau et al., "Structure-function studies of peptides inhibiting the ribonucleotide reductase activity of herpes simplex virus type 1," <u>J. Med. Chem.</u> , 35:346-350 (1992).
/CB/	C9	Girard et al., "Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses," <u>Eur. J. Clin. Pharmacol.</u> , 32:507-513 (1987).
/CB/	C10	Kimura et al., "Ultradian rhythm of growth hormone secretion and sleep in the adult male rat," <u>J. Physiol.</u> , 353:305-315 (1984).
/CB/	C11	Lapierre et al., "Effects of growth hormone-releasing factor and feed intake on energy metabolism in growing beef steers: Whole body energy and nitrogen metabolism," <u>J. Anim. Sci.</u> , 70:764-772 (1992).

EXAMINER /Christina Bradley/ (07/16/2007)	DATE CONSIDERED
--	------------------------



FOR PTO - 1449		ATTORNEY DOCKET NO.: BCF-001
SUPPLEMENTAL INFORMATION		APPLICANT(S): Gaudreau
DISCLOSURE STATEMENT		APPLICATION NO.: 10/527,598
		FILING DATE: November 3, 2005
		GROUP NO.: 1654
/CB/	C12	Lappier et al., "The effect of feed intake and growth hormone-release factor on lactating dairy cows," <u>J. Dairy Sci.</u> , 78:804-815 (1995).
/CB/	C13	Mitsugi et al., "Simultaneous determination of blood levels of corticosterone and growth hormone in the male rat: Relation to sleep-wakefulness cycle," <u>Neuroendocrinology</u> , 41:125-130 (1985).
/CB/	C14	Van Cauter et al., "Interrelations between sleep and the somatotrophic axis," <u>Sleep</u> , 21(6):553-566 (1998).

EXAMINER	/Christina Bradley/ (07/16/2007)	DATE CONSIDERED
----------	----------------------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/527,598
Filing Date	09/17/2003
First Named Inventor	Gaudreau, P
Art Unit	1654
Examiner Name	Christina Bradley
Attorney Docket Number	BCE-001

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

Examiner Signature	/Christina Bradley/ (07/16/2007)	Date Considered	
-----------------------	----------------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.